Arcus Biosciences, Inc.

RCUS · NYSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$283-$307-$267$53
Dep. & Amort.$10$8$14$4
Deferred Tax$0$0$0$5
Stock-Based Comp.$76$73$0$55
Change in WC$22-$71$623-$376
Other Non-Cash$5-$9$68$3
Operating Cash Flow-$170-$306$438-$256
Investing Activities
PP&E Inv.-$6-$24-$6-$26
Net Acquisitions$0$0$0-$22
Inv. Purchases-$1,043-$788-$1,241-$719
Inv. Sales/Matur.$965$1,006$837$741
Other Inv. Act.$0$0-$3$22
Investing Cash Flow-$84$194-$413-$4
Financing Activities
Debt Repay.$47$0$10$5
Stock Issued$228$25$23$220
Stock Repurch.$0$0$0-$0
Dividends Paid$0$0$0$0
Other Fin. Act.$2$8$0$12
Financing Cash Flow$277$33$33$237
Forex Effect$0$0$0$0
Net Chg. in Cash$23-$79$58-$23
Supplemental Information
Beg. Cash$130$209$148$174
End Cash$153$130$206$151
Free Cash Flow-$176-$330$432-$282